Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK9 | P45984 | 10/20 | 0.66 |
| ▸ | MAPK10 | P53779 | 10/20 | 0.66 |
| ▸ | TYK2 | P29597 | 5/20 | 0.58 |
| ▸ | JAK1 | P23458 | 4/20 | 0.58 |
| ▸ | JAK2 | O60674 | 3/20 | 0.58 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.53 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1231716 | 0.87 | MAPK9 (0.71) | MAPK9MAPK10TYK2JAK1JAK2 | |
| SCHEMBL1231866 | 0.86 | MAPK9 (0.70) | MAPK9MAPK10TYK2JAK1JAK2 | |
| SCHEMBL12102951 | 0.84 | MAPK10 (0.74) | MAPK9MAPK10TYK2JAK1JAK2 | |
| SCHEMBL1231920 | 0.83 | MAPK10 (0.72) | MAPK9MAPK10TYK2JAK1JAK2 | |
| SCHEMBL1232438 | 0.82 | MAPK9 (0.68) | MAPK9MAPK10TYK2JAK1JAK2 | |
| SCHEMBL1230831 | 0.81 | MAPK9 (0.69) | MAPK9MAPK10TYK2JAK1JAK2 | |
| SCHEMBL12900283 | 0.81 | MAPK10 (0.66) | MAPK9MAPK10PTK2MAPK3MAPK1 | |
| SCHEMBL1230967 | 0.81 | MAPK9 (0.71) | MAPK9MAPK10TYK2JAK1JAK2 | |
| SCHEMBL17689099 | 0.81 | TYK2 (0.78) | MAPK9MAPK10TYK2JAK1JAK2 | |
| SCHEMBL1560076 | 0.80 | MAPK10 (0.66) | MAPK9MAPK10TYK2JAK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580439-B2 | Inhibitors of focal adhesion kinase | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580439-B2 | Inhibitors of focal adhesion kinase | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580439-B2 | Inhibitors of focal adhesion kinase | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-02-28 | — | — | US | disclosed |
| EP-2727909-A1 | Inhibitors of focal adhesion kinase | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-05-07 | — | — | EP | disclosed |
| EP-2134689-B1 | INHIBITORS OF FOCAL ADHESION KINASE | SCRIPPS RESEARCH INST (US) | 2014-04-23 | — | — | EP | disclosed |
| EP-2134689-B1 | INHIBITORS OF FOCAL ADHESION KINASE | SCRIPPS RESEARCH INST (US) | 2014-04-23 | — | — | EP | disclosed |
| US-20130281443-A1 | INHIBITORS OF FOCAL ADHESION KINASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130281443-A1 | INHIBITORS OF FOCAL ADHESION KINASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130281443-A1 | INHIBITORS OF FOCAL ADHESION KINASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-10-24 | — | — | US | disclosed |
| US-8501763-B2 | Inhibitors of focal adhesion kinase | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501763-B2 | Inhibitors of focal adhesion kinase | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501763-B2 | Inhibitors of focal adhesion kinase | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-08-06 | — | — | US | disclosed |
| US-20110046121-A1 | INHIBITORS OF FOCAL ADHESION KINASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046121-A1 | INHIBITORS OF FOCAL ADHESION KINASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046121-A1 | INHIBITORS OF FOCAL ADHESION KINASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-02-24 | — | — | US | disclosed |
| WO-2008115369-A2 | INHIBITORS OF FOCAL ADHESION KINASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046121-A1 | INHIBITORS OF FOCAL ADHESION KINASE | PTK2, CABLES1, TNK2 | MAPK9 239/4885MAPK10 590/4885TYK2 445/4885 |
| US-20130281443-A1 | INHIBITORS OF FOCAL ADHESION KINASE | PTK2, CABLES1, TNK2 | MAPK9 239/4885MAPK10 590/4885TYK2 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.